Oncología Traslacional

Artículos Científicos

• Arias Ron D, Areses Manrique MC, Mosquera Martínez J, García González J, Afonso Afonso FJ, Lázaro Quintela M, Fernández Núñez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santomé Couto L, García Campelo MR, Muñoz Iglesias J, Ruiz Bañobre J, Vilchez Simo R, Casal Rubio J, Campos Balea B, Carou Frieiro I, Alonso-Jaudenes Curbera G, Anido Herranz U, García Mata J, Fírvida Pérez JL. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group. J Geriatr Oncol. 2021 Apr;12(3):410–5. PMID: 33357975. DOI: 10.1016/j.jgo.2020.11.010. http://www.ncbi.nlm.nih.gov/pubmed/33357975 +Pubmed +DOI
• Fernández Montes A, Martinez-Lago N, de la Cámara Gomez J, Brozos Vázquez EM, Candamio Folgar S, Carmona Campos M, Cousillas Castiñeiras A, Covela Rúa M, Gallardo Martín E, González Villarroel P, Graña Suarez B, Jorge Fernández M, Pellón Augusto ML, Quintero Aldana G, Romero Reinoso C, Salgado Fernández M, Vázquez Rivera F, Ayuso Álvarez A, Culqui DR, Méndez Méndez JC, RIGhT-Sens Working Group. Do Clinical Trials Meet Current Care Needs? Views of Digestive Oncology Specialists in Galicia (Spain) Using the Delphi Method. Healthc (Basel, Switzerland). 2021 Jun;9(6):665. PMID: 34205026. DOI: 10.3390/healthcare9060665. http://www.ncbi.nlm.nih.gov/pubmed/34205026 +Pubmed +DOI
• Majem M, Cobo M, Isla D, Marquez-Medina D, Rodriguez-Abreu D, Casal-Rubio J, Bueno TM, Bernabé-Caro R, Parente DP, Ruiz-Gracia P, Arroyo MM, Paz-Ares L. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. J Clin Med. 2021 Mar;10(7):1365. PMID: 33810441. DOI: 10.3390/jcm10071365. http://www.ncbi.nlm.nih.gov/pubmed/33810441 +Pubmed +DOI
• Martínez-Lago N, Fernández-Montes A, Covela M, Brozos EM, De la Cámara J, Méndez Méndez JC, Jorge-Fernández M, Cousillas Castiñeiras A, Reboredo C, Arias Ron D, Pellón Augusto ML, González Villarroel P, Graña B, Salgado Fernández M, Carral Maseda A, Vázquez Rivera F, Candamio Folgar S, Reboredo López M, Galician Research Group on Digestive Tumors (GITuD). Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. BMC Cancer. 2021 Jan;21(1):64. PMID: 33446148. DOI: 10.1186/s12885-020-07758-5. http://www.ncbi.nlm.nih.gov/pubmed/33446148 +Pubmed +DOI
• Martínez-Trufero J, De Sande-González LM, Luna P, Martin-Broto J, Álvarez R, Marquina G, Diaz-Beveridge R, Poveda A, Cano JM, Cruz-Jurado J, López Pousa A, Vaz Salgado MA, Valverde-Morales CM, Sevilla I, Martínez-García J, Rubio-Casadevall J, De Juan A, Carrasco JA, Moura DS, Gurruchaga-Sotes I, Gutiérrez A. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers (Basel). 2021 Feb;13(4) PMID: 33672857. DOI: 10.3390/cancers13040792. http://www.ncbi.nlm.nih.gov/pubmed/33672857 +Pubmed +DOI
• Pereira-Veiga T, González-Conde M, León-Mateos L, Piñeiro-Cid R, Abuín C, Muinelo-Romay L, Martínez-Fernández M, Brea Iglesias J, García González J, Anido U, Aguín-Losada S, Cebey V, Costa C, López-López R. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers. Clin Exp Metastasis. 2021 Apr;38(2):239–51. PMID: 33635497. DOI: 10.1007/s10585-021-10075-1. http://www.ncbi.nlm.nih.gov/pubmed/33635497 +Pubmed +DOI
• Ribelles N, Alvarez-Lopez I, Arcusa A, Chacon JI, de la Haba J, García-Corbacho J, Garcia-Mata J, Jara C, Jerez JM, Lázaro-Quintela M, Leon-Mateos L, Ramirez-Merino N, Tibau A, Garcia-Palomo A. Electronic health records and patient registries in medical oncology departments in Spain. Clin Transl Oncol. 2021 Apr;(E-PUB) PMID: 33864619. DOI: 10.1007/s12094-021-02614-9. http://www.ncbi.nlm.nih.gov/pubmed/33864619 +Pubmed +DOI
• Ruiz-Bañobre J, Molina-Díaz A, Fernández-Calvo O, Fernández-Núñez N, Medina-Colmenero A, Santomé L, Lázaro-Quintela M, Mateos-González M, García-Cid N, López-López R, Vázquez S, Anido-Herranz U. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study. ESMO open. 2021 Apr;6(2):100090. PMID: 33740735. DOI: 10.1016/j.esmoop.2021.100090. http://www.ncbi.nlm.nih.gov/pubmed/33740735 +Pubmed +DOI

Artículos Científicos

• Carmona-Bayonas A, Gómez D, Martínez de Castro E, Pérez Segura P, Muñoz Langa J, Jimenez-Fonseca P, Sánchez Cánovas M, Ortega Moran L, García Escobar I, Rupérez Blanco AB, Fernández Pérez I, Martínez de Prado P, Porta I Balanyà R, Quintanar Verduguez T, Rodríguez-Lescure Á, Muñoz A. A snapshot of cancer-associated thromboembolic disease in 2018-2019: First data from the TESEO prospective registry. Eur J Intern Med. 2020 Aug;78:41–9. PMID: 32482596. DOI: 10.1016/j.ejim.2020.05.031. http://www.ncbi.nlm.nih.gov/pubmed/32482596 +Pubmed +DOI
• Carvalho S, Abreu CM, Ferreira D, Lima L, Ferreira JA, Santos LL, Ribeiro R, Grenha V, Martínez-Fernández M, Duenas M, Suárez-Cabrera C, Paramio JM, Diéguez L, Freitas PP, Oliveira MI. Phenotypic Analysis of Urothelial Exfoliated Cells in Bladder Cancer via Microfluidic Immunoassays: Sialyl-Tn as a Novel Biomarker in Liquid Biopsies. Front Oncol. 2020;10:1774. PMID: 33042825. DOI: 10.3389/fonc.2020.01774. http://www.ncbi.nlm.nih.gov/pubmed/33042825 +Pubmed +DOI
• Fernandez Montes A, Vazquez Rivera F, Martinez Lago N, Covela Rúa M, Cousillas Castiñeiras A, Gonzalez Villarroel P, de la Cámara Gómez J, Méndez Méndez JC, Salgado Fernández M, Candamio Folgar S, Reboredo López M, Carmona Campos M, Gallardo Martín E, Jorge Fernández M, Pellón Augusto ML, París Bouzas L, García Gómez J. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. Clin Transl Oncol. 2020 Mar;22(3):351–9. PMID: 31073972. DOI: 10.1007/s12094-019-02130-x. http://www.ncbi.nlm.nih.gov/pubmed/31073972 +Pubmed +DOI
• García-González J, Ruiz-Bañobre J, Afonso-Afonso FJ, Amenedo-Gancedo M, Areses-Manrique MDC, Campos-Balea B, Casal-Rubio J, Fernández-Núñez N, Fírvida Pérez JL, Lázaro-Quintela M, Pérez Parente D, Crama L, Ruiz-Gracia P, Santomé-Couto L, León-Mateos L. PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis. J Clin Med. 2020 Jul;9(7):2093. PMID: 32635291. DOI: 10.3390/jcm9072093. http://www.ncbi.nlm.nih.gov/pubmed/32635291 +Pubmed +DOI
• González-Del-Alba A, Arranz JÁ, Bellmunt J, Maroto JP, Fernández-Calvo O, Valderrama BP, González-Billalabeitia E, Méndez-Vidal MJ, Cassinello J, Romero-Laorden N, Climent MÁ, Puente J, Peláez I, Lázaro-Quintela M, Gallardo E, Suárez C. Latest progress in molecular biology and treatment in genitourinary tumours. Clin Transl Oncol. 2020 Dec;22(12):2175–95. PMID: 32440915. DOI: 10.1007/s12094-020-02373-z. http://www.ncbi.nlm.nih.gov/pubmed/32440915 +Pubmed +DOI
• Guillén-Ponce C, Lastra E, Lorenzo-Lorenzo I, Martín Gómez T, Morales Chamorro R, Sánchez-Heras AB, Serrano R, Soriano Rodríguez MC, Soto JL, Robles L. SEOM clinical guideline on hereditary colorectal cancer (2019). Clin Transl Oncol. 2020 Feb;22(2):201–12. PMID: 31981079. DOI: 10.1007/s12094-019-02272-y. http://www.ncbi.nlm.nih.gov/pubmed/31981079 +Pubmed +DOI
• Isla D, Massuti B, Lázaro M, de Alda LR, Gordo R, Ortega-Joaquín N, Oyagüez I. Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib. Lung Cancer Manag. 2020 Mar;9(1):LMT28. PMID: 32256712. DOI: 10.2217/lmt-2019-0011. http://www.ncbi.nlm.nih.gov/pubmed/32256712 +Pubmed +DOI
• Lázaro M, Valderrama BP, Suárez C, De-Velasco G, Beato C, Chirivella I, González-Del-Alba A, Laínez N, Méndez-Vidal MJ, Arranz JA. SEOM clinical guideline for treatment of kidney cancer (2019). Clin Transl Oncol. 2020 Feb;22(2):256–69. PMID: 31993962. DOI: 10.1007/s12094-019-02285-7. http://www.ncbi.nlm.nih.gov/pubmed/31993962 +Pubmed +DOI
• Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M, GEICAM Spanish Breast Cancer Group, CIBOMA (Iberoamerican Coalition for Research in Breast Oncology), LACOG (Latin American Cooperative Oncology Group). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2020;38(3):203–13. PMID: 31804894. DOI: 10.1200/JCO.19.00904. http://www.ncbi.nlm.nih.gov/pubmed/31804894 +Pubmed +DOI
• Méndez Méndez JC, Salgado Fernández M, de la Cámara Gómez J, Pellón Augusto ML, Covela Rua M, Quintero Aldana G, Fernández Montes A, Reboredo López M, Valladares Ayerbes M, Jorge Fernández M, González Villarroel P, Romero Reinoso C, Ramos Vázquez M, Galician Research Group on Digestive Tumours (GITuD). First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study. J Geriatr Oncol. 2020;11(8):1263–7. PMID: 32580916. DOI: 10.1016/j.jgo.2020.06.003. http://www.ncbi.nlm.nih.gov/pubmed/32580916 +Pubmed +DOI
• Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413–22. PMID: 32979984. DOI: 10.1016/S1470-2045(20)30453-8. http://www.ncbi.nlm.nih.gov/pubmed/32979984 +Pubmed +DOI
• Quintero Aldana G, Salgado M, Candamio S, Méndez JC, Jorge M, Reboredo M, Vázquez Tuñas L, Romero C, Covela M, Fernández Montes A, Carmona M, Vidal Insua Y, López R, Galician Oncological Research Group (GGIO). First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial. Clin Transl Oncol. 2020 Apr;22(4):495–502. PMID: 31280434. DOI: 10.1007/s12094-019-02151-6. http://www.ncbi.nlm.nih.gov/pubmed/31280434 +Pubmed +DOI
• Ruano-Raviña A, Provencio M, Calvo de Juan V, Carcereny E, Moran T, Rodriguez-Abreu D, López-Castro R, Cuadrado Albite E, Guirado M, Gómez González L, Massutí B, Ortega Granados AL, Blasco A, Cobo M, Garcia-Campelo R, Bosch J, Trigo J, Juan Ó, Aguado de la Rosa C, Dómine M, Sala M, Oramas J, Casal-Rubio J, Cerezo S. Lung cancer symptoms at diagnosis: results of a nationwide registry study. ESMO open. 2020;5(6):e001021. PMID: 33214227. DOI: 10.1136/esmoopen-2020-001021. http://www.ncbi.nlm.nih.gov/pubmed/33214227 +Pubmed +DOI
• Vázquez Estévez S, Anido U, Lázaro M, Fernández O, Fernández Núñez N, de Dios Álvarez N, Varela V, Campos Balea B, Agraso S, Areses MC, Iglesias L, Blanco M, Maciá S, Anton Aparicio LM. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus. Clin Transl Oncol. 2020 Sep;22(9):1565–79. PMID: 32062835. DOI: 10.1007/s12094-020-02300-2. http://www.ncbi.nlm.nih.gov/pubmed/32062835 +Pubmed +DOI

Artículos Científicos

• Anido-Herranz U, Fernández-Núñez N, Afonso-Afonso J, Santomé-Couto L, Medina-Colmenero A, Fernández-Calvo O, Lázaro-Quintela M, Vázquez S. Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer. Clin Transl Oncol. 2019 Mar;21(3):249–58. PMID: 30051212. DOI: 10.1007/s12094-018-1928-y. http://www.ncbi.nlm.nih.gov/pubmed/30051212 +Pubmed +DOI
• Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. J Thorac Oncol. 2019;14(12):2120–32. PMID: 31349061. DOI: 10.1016/j.jtho.2019.07.005. http://www.ncbi.nlm.nih.gov/pubmed/31349061 +Pubmed +DOI
• Dueñas M, Pérez-Figueroa A, Oliveira C, Suárez-Cabrera C, Sousa A, Oliveira P, Villacampa F, Paramio JM, Martínez-Fernández M. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. Sci Rep. 2019;9(1):10362. PMID: 31316092. DOI: 10.1038/s41598-019-46652-4. http://www.ncbi.nlm.nih.gov/pubmed/31316092 +Pubmed +DOI
• Fernández Montes A, Martínez Lago N, Covela Rúa M, de la Cámara Gómez J, González Villaroel P, Méndez Méndez JC, Jorge Fernández M, Salgado Fernández M, Reboredo López M, Quintero Aldana G, Luz Pellón Augusto M, Graña Suárez B, García Gómez J. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Med. 2019 Mar;8(3):882–9. PMID: 30690930. DOI: 10.1002/cam4.1903. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434192/pdf/CAM4-8-882.pdf +Pubmed +DOI
• Leiro-Fernández V, Mouronte-Roibás C, García-Rodríguez E, Botana-Rial M, Ramos-Hernández C, Torres-Durán M, Ruano-Raviña A, Fernández-Villar A, Lung Cancer Group at the Álvaro Cunqueiro Hospital in Vigo (Manuel Núñez?Delgado; Carlos Vilariño?Pombo; Ana González?Piñeiro; Eva García?Fontán; Montserrat Blanco?Ramos; Miguel Ángel Cañizares?Carretero; Paula Rodríguez?Fernández; Amara Tilve?Gómez; Elen. Predicting delays in lung cancer diagnosis and staging. Thorac cancer. 2019 Feb;10(2):296–303. PMID: 30605236. DOI: 10.1111/1759-7714.12950. http://www.ncbi.nlm.nih.gov/pubmed/30605236 +Pubmed +DOI
• Martinez VG, Munera-Maravilla E, Bernardini A, Rubio C, Suarez-Cabrera C, Segovia C, Lodewijk I, Dueñas M, Martínez-Fernández M, Paramio JM. Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. Front Genet. 2019;10:1125. PMID: 31850055. DOI: 10.3389/fgene.2019.01125. http://www.ncbi.nlm.nih.gov/pubmed/31850055 +Pubmed +DOI
• Muñoz E, Domingo J, De Castro G, Lorenzo I, García-Velasco JA, Bellver J, Pellicer A, Garrido N. Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer. Reprod Biomed Online. 2019 Nov;39(5):860–7. PMID: 31564650. DOI: 10.1016/j.rbmo.2019.07.003. http://www.ncbi.nlm.nih.gov/pubmed/31564650 +Pubmed +DOI
• Pereira-Veiga T, Martínez-Fernández M, Abuin C, Piñeiro R, Cebey V, Cueva J, Palacios P, Blanco C, Muinelo-Romay L, Abalo A, Costa C, López-López R. CTCs Expression Profiling for Advanced Breast Cancer Monitoring. Cancers (Basel). 2019 Dec;11(12) PMID: 31817194. DOI: 10.3390/cancers11121941. http://www.ncbi.nlm.nih.gov/pubmed/31817194 +Pubmed +DOI
• Provencio M, Carcereny E, Rodríguez-Abreu D, López-Castro R, Guirado M, Camps C, Bosch-Barrera J, García-Campelo R, Ortega-Granados AL, González-Larriba JL, Casal-Rubio J, Domine M, Massutí B, Sala MÁ, Bernabé R, Oramas J, Del Barco E. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Transl lung cancer Res. 2019 Aug;8(4):461–75. PMID: 31555519. DOI: 10.21037/tlcr.2019.08.05. http://www.ncbi.nlm.nih.gov/pubmed/31555519 +Pubmed +DOI
• Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol. Springer Berlin Heidelberg; 2019;83(6):1175–81. PMID: 30927036. DOI: 10.1007/s00280-019-03820-7. http://www.ncbi.nlm.nih.gov/pubmed/30927036 +Pubmed +DOI
• Rubio C, Martínez-Fernández M, Segovia C, Lodewijk I, Suarez-Cabrera C, Segrelles C, López-Calderón F, Munera-Maravilla E, Santos M, Bernardini A, García-Escudero R, Lorz C, Gómez-Rodriguez MJ, de Velasco G, Otero I, Villacampa F, Guerrero-Ramos F, Ruiz S, de la Rosa F, Domínguez-Rodríguez S, Real FX, Malats N, Castellano D, Dueñas M, Paramio JM. CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status. Clin Cancer Res. 2019;25(1):390–402. PMID: 30242024. DOI: 10.1158/1078-0432.CCR-18-0685. http://www.ncbi.nlm.nih.gov/pubmed/30242024 +Pubmed +DOI
• Ruiz-Bañobre J, Areses-Manrique MC, Mosquera-Martínez J, Cortegoso A, Afonso-Afonso FJ, de Dios-Álvarez N, Fernández-Núñez N, Azpitarte-Raposeiras C, Amenedo M, Santomé L, Fírvida-Pérez JL, García-Campelo R, García-González J, Casal-Rubio J, Vázquez S. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl lung cancer Res. 2019 Dec;8(6):1078–85. PMID: 32010585. DOI: 10.21037/tlcr.2019.11.07. http://www.ncbi.nlm.nih.gov/pubmed/32010585 +Pubmed +DOI
• Santaballa A, De Castro J, Maurel J, Lázaro M, Vera R, Alba E. Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol. 2019 Apr;21(4):534–8. PMID: 30327937. DOI: 10.1007/s12094-018-1951-z. http://www.ncbi.nlm.nih.gov/pubmed/30327937 +Pubmed +DOI
• Segovia C, San José-Enériz E, Munera-Maravilla E, Martínez-Fernández M, Garate L, Miranda E, Vilas-Zornoza A, Lodewijk I, Rubio C, Segrelles C, Valcárcel LV, Rabal O, Casares N, Bernardini A, Suarez-Cabrera C, López-Calderón FF, Fortes P, Casado JA, Dueñas M, Villacampa F, Lasarte JJ, Guerrero-Ramos F, de Velasco G, Oyarzabal J, Castellano D, Agirre X, Prósper F, Paramio JM. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Nat Med. 2019;25(7):1073–81. PMID: 31270502. DOI: 10.1038/s41591-019-0499-y. http://www.ncbi.nlm.nih.gov/pubmed/31270502 +Pubmed +DOI

Guías de Práctica Clínica

• Campos Balea B, Fernández Bouza E, Barbagelata López C, Brozos Vázquez EM, CAROU FRIEIRO, IRIA; Fernández Pérez I, Iglesias Rey L, Quindós Varela M, Carmona Campos M, Antolín Novoa S. Guía gallega de manejo de la trombosis asociada a cáncer. Rivera Gallego A, Lopez-Lopez R (eds.). Barcelona: Bubblegum Communication Services; 2019. Con el Aval de la Sociedad Oncológica de Galicia (. ISBN: 978-84-09-1419-4. https://runa.sergas.es/xmlui/handle/20.500.11940/12881 Enlace

Artículos Científicos

• Areses Manrique MC, Mosquera Martínez J, García González J, Afonso Afonso FJ, Lázaro Quintela M, Fernández Núñez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santomé Couto L, García Campelo MR, Muñoz Iglesias J, Cortegoso Mosquera A, Vilchez Simo R, Casal Rubio J, Campos Balea B, Carou Frieiro I, Alonso-Jaudenes Curbera G, Anido Herranz U, García Mata J, Fírvida Pérez JL. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl lung cancer Res. 2018 Jun;7(3):404–15. PMID: 30050778. DOI: 10.21037/tlcr.2018.04.03. http://www.ncbi.nlm.nih.gov/pubmed/30050778 +Pubmed +DOI
• Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, Climent MÁ, Olmos D, Carles J, Lázaro M. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):57–68. PMID: 29134562. DOI: 10.1007/s12094-017-1783-2. http://www.ncbi.nlm.nih.gov/pubmed/29134562 +Pubmed +DOI
• Costa Rivas M, Huidobro Vence G, Fírvida Pérez JL, Campos Balea B, García Gonzalez J, Lázaro Quintela M, Caeiro Muñoz M, Taboada Valladares B, Castro Gómez JE, Vázquez Estevez S, Afonso Afonso FJ, Azpitarte Raposeiras C, Amenedo Gancedo M, Casal Rubio J. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group. Clin Transl Oncol. 2018 Nov;20(11):1467–73. PMID: 29696478. DOI: 10.1007/s12094-018-1880-x. http://www.ncbi.nlm.nih.gov/pubmed/29696478 +Pubmed +DOI
• Fernández A, Salgado M, García A, Buxò E, Vera R, Adeva J, Jiménez-Fonseca P, Quintero G, Llorca C, Cañabate M, López LJ, Muñoz A, Ramírez P, González P, López C, Reboredo M, Gallardo E, Sanchez-Cánovas M, Gallego J, Guillén C, Ruiz-Miravet N, Navarro-Pérez V, De la Cámara J, Alés-Díaz I, Pazo-Cid RA, Carmona-Bayonas A. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer. BMC Cancer; 2018 Nov;18(1):1185. PMID: 30497432. DOI: 10.1186/s12885-018-5101-3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267080/pdf/12885_2018_Article_5101.pdf +Pubmed +DOI
• Losa F, Soler G, Casado A, Estival A, Fernández I, Giménez S, Longo F, Pazo-Cid R, Salgado J, Seguí MÁ. SEOM clinical guideline on unknown primary cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):89–96. PMID: 29230692. DOI: 10.1007/s12094-017-1807-y. http://www.ncbi.nlm.nih.gov/pubmed/29230692 +Pubmed +DOI
• Paumard-Hernández B, Calvete O, Inglada Pérez L, Tejero H, Al-Shahrour F, Pita G, Barroso A, Carlos Triviño J, Urioste M, Valverde C, González Billalabeitia E, Quiroga V, Francisco Rodríguez Moreno J, Fernández Aramburo A, López C, Maroto P, Sastre J, José Juan Fita M, Duran I, Lorenzo-Lorenzo I, Iranzo P, García Del Muro X, Ros S, Zambrana F, María Autran A, Benítez J. Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. Int J cancer. 2018 May;143(8):1954–62. PMID: 29761480. DOI: 10.1002/ijc.31604. http://www.ncbi.nlm.nih.gov/pubmed/29761480 +Pubmed +DOI
• Ruiz-Llorente L, Contreras-Jurado C, Martínez-Fernández M, Paramio JM, Aranda A. Thyroid Hormone Receptors Regulate the Expression of microRNAs with Key Roles in Skin Homeostasis. Thyroid. 2018;28(7):921–32. PMID: 29742977. DOI: 10.1089/thy.2017.0369. http://www.ncbi.nlm.nih.gov/pubmed/29742977 +Pubmed +DOI
• Sabell Pérez-Salgado F, Vázquez-Estévez S, Anido-Herranz U, Blanco-Parra M, Casas-Nebra FJ, Fernández-Calvo O, Lázaro-Quintela M, López-García S. Approach of the patient with renal cancer: Is there a collaboration between urology and oncology? Actas Urol Esp. 2018 Jan;42(1):1–4. PMID: 28587846. DOI: 10.1016/j.acuro.2017.04.001. http://www.ncbi.nlm.nih.gov/pubmed/28587846 +Pubmed +DOI
• Suárez-Cabrera C, de la Peña B, González LL, Page A, Martínez-Fernández M, Casanova ML, Paramio JM, Rojo-Sebastián A, Moreno-Bueno G, Maroto A, Ramírez Á, Navarro M. The Ras-related gene ERAS is involved in human and murine breast cancer. Sci Rep. 2018;8(1):13038. PMID: 30158566. DOI: 10.1038/s41598-018-31326-4. http://www.ncbi.nlm.nih.gov/pubmed/30158566 +Pubmed +DOI

Artículos Científicos

• Areses M, Campelo RG, García González J, Afonso FJ, Lazaro ME, Campos B, Azpitarte C, Amenedo M, Santomé L, Ron DA, Alonso-Jaudenes G, Baron F, Vilchez R, Casal J, Fernandez N, Carou I, Mosquera J, Anido U, Garcia Mata J, Firvida J. The real-world experience with nivolumab in previously treated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group clinical practice. J Clin Oncol. 2017 May;35(15_suppl):e20564. DOI: 10.1200/JCO.2017.35.15_suppl.e20564. IF2017: 26.360; D1. http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e20564 +DOI
• Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, Ocana A. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev. 2017 May;56:1–7. PMID: 28437678. DOI: 10.1016/j.ctrv.2017.03.011. IF2017: 8.122; D1. http://www.ncbi.nlm.nih.gov/pubmed/28437678 +Pubmed +DOI
• Cameselle-Teijeiro JF, Valdés-Pons J, Cameselle-Cortizo L, Fernández-Pérez I, Lamas-González MJ, Iglesias-Faustino S, Alonso-Figueirido E, Cortizo-Torres M-E, Agras-Suárez M-C, Iglesias-Salgado A, Salgado-Costas M, Friande-Pereira S, Schmitt FC. Tumours of the Uterine Corpus: A Histopathological and Prognostic Evaluation Preliminary of 429 Patients. J Clin Med Exp Images. 2017;1(1):011–9. DOI: 10.29328/journal.jcmei.1001004. IF2017: N/A. https://www.heighpubs.org/jcmei/jcmei-aid1004.php +DOI
• De Castro J, González-Larriba JL, Vázquez S, Massutí B, Sanchez-Torres JM, Dómine M, Garrido P, Calles A, Artal A, Collado R, García R, Sereno M, Majem M, Macías JA, Juan O, Gómez-Codina J, Hernández B, Lázaro M, Ortega AL, Cobo M, Trigo JM, Carcereny E, Rolfo C, Macia S, Muñoz J, Diz P, Méndez M, Rosillo F, Paz-Ares L, Cardona J V, Isla D. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. Clin Transl Oncol. 2017 Feb;19(2):219–26. PMID: 27371031. DOI: 10.1007/s12094-016-1527-8. IF2017: 2.392; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27371031 +Pubmed +DOI
• Feber A, Dhami P, Dong L, de Winter P, Tan WS, Martínez-Fernández M, Paul DS, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng KK, Zeegers MP, Bryan RT, James ND, Paramio JM, Freeman A, Beck S, Kelly JD. UroMark-a urinary biomarker assay for the detection of bladder cancer. Clin Epigenetics. 2017;9:8. PMID: 28163793. DOI: 10.1186/s13148-016-0303-5. http://www.ncbi.nlm.nih.gov/pubmed/28163793 +Pubmed +DOI
• Gomez Garcia S, Costa Rivas M, Areses Manrique MC, Fernández Núñez N, Garcia J, Caeiro M, Castro E, Formoso I, Calvo P, De Dios Alvarez N, Firvida J, Campos B, Azpitarte C, Afonso FJ, Amenedo M, Casal Rubio J. Concurrent chemoradiation (CChRT) for locally advanced stage III non-small cell lung cancer (NSCLC) with cisplatin and vinorelbine and thoracic radiotherapy: A phase II study from the Galician Lung Cancer Group. J Clin Oncol. 2017 May;35(15_suppl):e20067. DOI: 10.1200/JCO.2017.35.15_suppl.e20067. IF2017: 26.360; D1. http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e20067 +DOI
• González Del Alba A, Arranz JÁ, Puente J, Méndez-Vidal MJ, Gallardo E, Grande E, Pérez-Valderrama B, González-Billalabeitia E, Lázaro-Quintela M, Pinto Á, Lainez N, Piulats JM, Esteban E, Maroto Rey JP, García JA, Suárez C. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Crit Rev Oncol Hematol. 2017 May;113:171–90. PMID: 28427506. DOI: 10.1016/j.critrevonc.2017.03.010. IF2017: 4.495; Q1. http://www.ncbi.nlm.nih.gov/pubmed/28427506 +Pubmed +DOI
• González-Larriba JL, Lázaro-Quintela M, Cobo M, Dómine M, Majem M, García-Campelo R. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Transl lung cancer Res. 2017 Dec;6(Suppl 1):S21–34. PMID: 29299405. DOI: 10.21037/tlcr.2017.10.03. IF2017: N/A. http://www.ncbi.nlm.nih.gov/pubmed/29299405 +Pubmed +DOI
• Lorenzo-Lorenzo I, Fernández-Pérez I, Alonso-Herrero A, Villanueva-Sil MJ. Breast Cancer Chemoprevention: What and When? Cancer Chemother Rev. 2017;12(2):46–57. IF2017: N/A. http://www.cancerchemotherapyreviews.com/resumen.asp?id=860&indice=2017122 Enlace
• Martin Jimenez M, Calvo Ferrandiz A, Aparicio Urtasun J, Garcia-Campelo R, Gonzalez-Flores E, Lazaro Quintela M, Muñoz Mateu M, Rodriguez Sanchez CA, Santaballa Bertran A, Sepulveda Sanchez JM, Vera Garcia R, Virizuela Echaburu JA, Segui Palmer MA. New clinical trials regulation in Spain: analysis of royal decree 1090/2015. Clin Transl Oncol. 2017 Mar;19(3):291–300. PMID: 27718157. DOI: 10.1007/s12094-016-1550-9. IF2017: 2.392; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27718157 +Pubmed +DOI
• Martínez VG, Rubio C, Martínez-Fernández M, Segovia C, López-Calderón F, Garín MI, Teijeira A, Munera-Maravilla E, Varas A, Sacedón R, Guerrero F, Villacampa F, de la Rosa F, Castellano D, López-Collazo E, Paramio JM, Vicente Á, Dueñas M. BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer. Clin Cancer Res. 2017 Dec;23(23):7388–99. PMID: 28928159. DOI: 10.1158/1078-0432.CCR-17-1004. http://www.ncbi.nlm.nih.gov/pubmed/28928159 +Pubmed +DOI
• Méndez Méndez JC, Ramos M, De la Cámara Gómez JC, Pellón ML, Covela M, Quintero Aldana GA, Salgado Fernandez M, Fernández-Montes A, Reboredo M, Valladares-Ayerbes M, Jorge Fernandez M, González Villarroel P, Romero Reinoso C. 553P – First-line panitumumab (P) plus capecitabine (C) for the treatment of elderly patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Preliminary results of the phase II, PANEL GITuD-2011-01 study. Ann Oncol. 2017 Sep;28(suppl_5):553P. DOI: 10.1093/annonc/mdx393.079. IF2017: 13.930; D1. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx393.079/4109851/553PFirstline-panitumumab-P-plus-capecitabine-C +DOI
• Ocana Fernandez A, Ruiz Borrego M, Gil Martin M, Antolin S, Atienza M, Montaño A, Ribelles N, Guerrero A, Muñoz M, Fernández-Pérez I, Urruticoechea A, Falcon Gonzalez A, Pernas Simon S, Prato Varela J, Escudero MJ, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A. 239PD – A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04. Ann Oncol. 2017 Sep;28(suppl_5):239PD. DOI: 10.1093/annonc/mdx365.002. IF2017: 13.930; D1; JCR-CAT: ONCOLOGY. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.002/4108468/239PDA-phase-II-trial-of-dasatinib-D-in +DOI
• Perez-Segura P, Palacio JE, Vazquez L, Monereo S, de Las Penas R, de Icaya PMM, Gravalos C, Lecube A, Blasco A, Garcia-Almeida JM, Barneto I, Goday A, Pérez-Segura P, Palacio JE, Vázquez L, Monereo S, de Las Peñas R, de Icaya PMM, Grávalos C, Lecube A, Blasco A, García-Almeida JM, Barneto I, Goday A. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2017 Jun;19(6):682–94. PMID: 28074400. DOI: 10.1007/s12094-016-1601-2. IF2017: 2.392; Q3. http://www.ncbi.nlm.nih.gov/pubmed/28074400 +Pubmed +DOI
• Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, Del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM, SOGUG (Spanish Oncology Genitourinary Group). Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. Oncotarget. 2017 May;8(18):30410–21. PMID: 28423742. DOI: 10.18632/oncotarget.16494. http://www.ncbi.nlm.nih.gov/pubmed/28423742 +Pubmed +DOI
• Segovia C, Martínez-Fernández M, Dueñas M, Rubio C, López-Calderón FF, Costa C, Saiz-Ladera C, Fernández-Grajera M, Duarte J, Muñoz HG, de la Rosa F, Villacampa F, Castellano D, Paramio JM. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer. Oncotarget. 2017 Feb;8(6):10531–42. PMID: 28060766. DOI: 10.18632/oncotarget.14453. http://www.ncbi.nlm.nih.gov/pubmed/28060766 +Pubmed +DOI
• Segovia C, Paramio JM, Martínez-Fernández M. Epigenetic mutations and cancer therapy Effectiven(EZH2). Transl Cancer Res. 2017 May;6(S3):S629–34. DOI: 10.21037/tcr.2017.05.27. http://doi.org/10.21037/tcr.2017.05.27 +DOI
• Vera R, Gómez M, Ayuso JR, Figueras J, Garcia-Alfonso P, Martinez V, Lacasta A, Ruiz A, Safont MJ, Aparicio J, Campos J, Cámara J, Martin M, Montagut C, Pericay C, Viéitez JM, Falcó E, Jorge M, Marín Vera M, Salgado Fernandez M. 590P – Correlation between RECIST-criteria, morphologic response by CT and pathologic regression in hepatic metastasis secondary to colorectal cancer: The AVAMET study. Ann Oncol. 2017 Sep;28(suppl_5):590P. DOI: 10.1093/annonc/mdx393.115. IF2017: 13.930; D1. http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx393.115/4109887/590PCorrelation-between-RECISTcriteria-morphologic +DOI

Capítulos de libro

• Fernández-Pérez I, Alonso-Herrero A, Gómez-García S, Costa-Rivas M. Enfermedad Tromboembólica Venosa y Cáncer de Ovario. Oncology Thrombosis Risk. Esmon Publicidad; 2017. ISBN: 9788494660511. https://books.google.es/books/about/Enfermedad_tromboembólica_venosa_y_cán.html?id=UwrNwQEACAAJ&redir_esc=y Enlace

Guías de Práctica Clínica

• Álvarez López J, Fernández-Calvo O, Charín Pato G. Fisterra Guías Clínicas: Melanoma cutáneo. 2017. https://www.fisterra.com/guias-clinicas/melanoma-cutaneo/#27021 Enlace
• Fírvida-Pérez JL, Arias-Ron D, Fernández-Calvo O. Fisterra Guías Clínicas: Cáncer de pulmón. 2017. https://www.fisterra.com/guias-clinicas/cancer-pulmon/#26990 Enlace
• Lamelo-Alfonsín F, Charlín-Pato G, Fernandez-Calvo O. Fisterra Guías Clínicas: Efectos secundarios del tratamiento oncológico. 2017. https://www.fisterra.com/guias-clinicas/efectos-secundarios-tratamiento-oncologico/#26976 Enlace

Artículos Científicos

• Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernández-Pérez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016 May;127(3):569–79. PMID: 26847813. DOI: 10.1007/s11060-016-2065-5. IF2016: 2.980; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26847813 +Pubmed +DOI
• Cameselle-Teijeiro JF, Cameselle-Cortizo L, Valdés-Pons J, Fernández-Pérez I, Lamas-González M, Iglesias-Faustino S, Figueiredo-Alonso E, Cortizo-Torres M, Iglesias-Salgado A, Salgado-Costas M, Schmitt F. Breast Cancer and Ovarian Cancer in Monozygotic Twins. Clin Oncol. 2016;1:1016. IF2016: N/A. https://adicam.net/files/DOC-20160729-WA0012.pdf Enlace
• Costa C, Santos M, Martínez-Fernández M, Lorz C, Lázaro S, Paramio JM. Deregulation of the pRb-E2F4 axis alters epidermal homeostasis and favors tumor development. Oncotarget. 2016;7(46):75712–28. PMID: 27708231. DOI: 10.18632/oncotarget.12362. http://www.ncbi.nlm.nih.gov/pubmed/27708231 +Pubmed +DOI
• Estévez SV, Herranz UA, Calvo OF, Afonso Afonso FJ, Couto LS, Lázaro-Quintela M, Mateos LL, Maciá Escalante S. Prostate cancer perspectives after chaarted: Optimizing treatment sequence. Crit Rev Oncol Hematol. Elsevier Ireland Ltd; 2016 Nov;107:119–27. PMID: 27823639. DOI: 10.1016/j.critrevonc.2016.08.007. IF2016: 4.491; Q1. http://www.ncbi.nlm.nih.gov/pubmed/27823639 +Pubmed +DOI
• Fonseca PJ, Carmona-Bayonas A, García IM, Marcos R, Castañón E, Antonio M, Font C, Biosca M, Blasco A, Lozano R, Ramchandani A, Beato C, de Castro EM, Espinosa J, Martínez-García J, Ghanem I, Cubero JH, Manrique IA, Navalón FG, Sevillano E, Manzano A, Virizuela J, Garrido M, Mondéjar R, Arcusa MÁ, Bonilla Y, Pérez Q, Gallardo E, del Carmen Soriano M, Cardona M, Lasheras FS, Cruz JJ, Ayala F, Spanish Soc Med Oncology SEOM, FINITE Investigators. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. Br J Cancer. 2016 May;114(11):1191–8. PMID: 27187687. DOI: 10.1038/bjc.2016.118. IF2016: 6.176; Q1. http://www.ncbi.nlm.nih.gov/pubmed/27187687 +Pubmed +DOI
• García J, Santomé L, Anido U, Fernández-Calvo O, Afonso-Afonso J, Lázaro M, Medina A, Vázquez Estévez S. Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU). Curr Oncol Rep. 2016 Dec;18(12):72. PMID: 27812861. DOI: 10.1007/s11912-016-0556-3. IF2016: 2.608; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27812861 +Pubmed +DOI
• Gómez García S, Clemons M, Amir E. Rethinking end-points for bone-targeted therapy in advanced cancer. Eur J Cancer. 2016 Aug;63:105–9. PMID: 27299662. DOI: 10.1016/j.ejca.2016.05.014. IF2016: 6.029; Q1. http://www.ncbi.nlm.nih.gov/pubmed/27299662 +Pubmed +DOI
• Lainez N, García-Donas J, Esteban E, Puente J, Sáez MI, Gallardo E, Pinto-Marín Á, Vázquez-Estévez S, León L, García-Carbonero I, Suárez-Rodríguez C, Molins C, Climent-Duran MA, Lázaro-Quintela M, González Del Alba A, Méndez-Vidal MJ, Chirivella I, Afonso FJ, López-Brea M, Sala-González N, Domenech M, Basterretxea L, Santander-Lobera C, Gil-Arnáiz I, Fernández O, Caballero-Díaz C, Mellado B, Marrupe D, García-Sánchez J, Sánchez-Escribano R, Fernández Parra E, Villa Guzmán JC, Martínez-Ortega E, Belén González M, Morán M, Suarez-Paniagua B, Lecumberri MJ, Castellano D. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. BMC Cancer. 2016 Feb;16(1):135. PMID: 26906039. DOI: 10.1186/s12885-016-2084-9. IF2016: 3.288; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26906039 +Pubmed +DOI
• Lázaro M, Gallardo E, Doménech M, Pinto Á, Del Alba AG, Puente J, Fernández O, Font A, Lainez N, Vázquez S. SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). Clin Transl Oncol. 2016 Dec;18(12):1197–205. PMID: 27900539. DOI: 10.1007/s12094-016-1584-z. IF2016: 2.353; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27900539 +Pubmed +DOI
• López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, Garcia Del Muro X. SEOM Clinical Guideline of management of soft-tissue sarcoma (2016). Clin Transl Oncol. 2016 Dec;18(12):1213–20. PMID: 27905051. DOI: 10.1007/s12094-016-1574-1. IF2016: 2.353; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27905051 +Pubmed +DOI
• Martínez-Fernández M, Paramio JM, Dueñas M. RNA Detection in Urine: From RNA Extraction to Good Normalizer Molecules. J Mol Diagn. 2016 Jan;18(1):15–22. PMID: 26586227. DOI: 10.1016/j.jmoldx.2015.07.008. http://www.ncbi.nlm.nih.gov/pubmed/26586227 +Pubmed +DOI
• Martínez-Jañez N, Chacón I, de Juan A, Cruz-Merino L, Del Barco S, Fernández I, García-Teijido P, Gómez-Bernal A, Plazaola A, Ponce J, Servitja S, Zamora P. Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel. Breast Care (Basel). 2016 Apr;11(2):133–8. PMID: 27239176. DOI: 10.1159/000443601. IF2016: 1.553; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27239176 +Pubmed +DOI
• Pena C, Alvarez M, Fernández Núñez N, Alonso Herrero A, Amenedo M, Firvida Perez JL, Campos Balea BÂ, Gomez Garcia S, Covela Rúa M, Costa Rivas M, Cadavid Vieitez L, Vazquez-Estevez S. ERCC1 expression in tumor tissue as biomarker of outcomes of oral vinorelbine-cisplatin (oVP) combination in metastatic squamous cell lung cancer (SqLC): A prospective study—GGCP 052/12. J Clin Oncol. 2016 May;34(15_suppl):e20533. DOI: 10.1200/JCO.2016.34.15_suppl.e20533. http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e20533 +DOI
• Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Clin Transl Oncol. 2016 Aug;18(8):805–12. PMID: 26542177. DOI: 10.1007/s12094-015-1444-2. IF2016: 2.353; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26542177 +Pubmed +DOI
• Pérez-Valderrama B, Arranz Arija JA, Rodríguez Sánchez A, Pinto Marín A, Borrega García P, Castellano Gaunas DE, Rubio Romero G, Maximiano Alonso C, Villa Guzmán JC, Puertas Álvarez JL, Chirivella González I, Méndez Vidal MJ, Juan Fita MJ, León-Mateos L, Lázaro Quintela M, García Domínguez R, Jurado García JM, Vélez de Mendizábal E, Lambea Sorrosal JJ, García Carbonero I, González del Alba A, Suárez Rodríguez C, Jiménez Gallego P, Meana García JA, García Marrero RD, Gajate Borau P, Santander Lobera C, Molins Palau C, López Brea M, Fernández Parra EM, Reig Torras O, Basterretxea Badiola L, Vázquez Estévez S, González Larriba JL. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Ann Oncol Off J Eur Soc Med Oncol. 2016 Apr;27(4):706–11. PMID: 26658889. DOI: 10.1093/annonc/mdv601. IF2016: 11.855; D1. http://www.ncbi.nlm.nih.gov/pubmed/2 +Pubmed +DOI
• Sánchez-Ares M, Cameselle-Teijeiro JM, Vázquez-Estévez S, Lázaro-Quintela M, Vázquez-Boquete Á, Afonso-Afonso FJ, Casal-Rubio J, González-Piñeiro AL, Rico-Rodríguez Y, Fírvida-Pérez JL, Ruíz-Bañobre J, Couso E, Santomé L, Pérez-Becerra R, García-Campelo R, Amenedo M, Azpitarte-Raposeiras C, Antúnez J, Abdulkader I. Fluorescence in situ hybridization analysis of the ALK gene in 2,045 non-small cell lung cancer patients from North-Western Spain (Galicia). Oncol Lett. 2016 Aug;12(2):1403–7. PMID: 27446444. DOI: 10.3892/ol.2016.4788. IF2016: 1.390; Q4. http://www.ncbi.nlm.nih.gov/pubmed/27446444 +Pubmed +DOI
• Vázquez S, Casal J, Afonso Afonso FJ, Fírvida JL, Santomé L, Barón F, Lázaro M, Pena C, Amenedo M, Abdulkader I, González-Arenas C, Fachal L, Vega A. EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Manag Res. 2016 Feb;8:11–20. PMID: 26893581. DOI: 10.2147/CMAR.S85173. IF2016: 3.851; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26893581 +Pubmed +DOI

Capítulos de libro

• Lorenzo-Lorenzo I. TNE torácicos: pulmón y timo. Guía práctica de diagnóstico, tratamiento y seguimiento de tumores neuroendocrinos. Versión 3. EdikaMed S.L; 2016. p. 51–70. ISBN: 978-84-7877-892-8. http://www.getne.org/LinkClick.aspx?fileticket=lxEtmyHm2NI%3D Enlace

Guías de Práctica Clínica

• Lázaro-Quintela M, Vázquez-Éstevez S, León-Mateos L, Grande-Pulido E, Antón-Aparicio L. Tratado de tumores raros. Grupo GETHI; 2016. ISBN: 978-84-697-0596-4. http://www.tratadodetumoresraros.com/ Enlace

Artículos Científicos

• Anido Herranz U, Fernández Calvo O, Afonso Afonso FJ, Rodríguez Martínez de Llano S, Lázaro Quintela M, León Mateos L, Vázquez Estévez S, Antón Aparicio LM. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015 Mar;15(3):339–48. PMID: 25555355. DOI: 10.1586/14737140.2015.999045. IF2015: 2.094; Q3. http://www.ncbi.nlm.nih.gov/pubmed/25555355 +Pubmed +DOI
• Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, Ramchandani A, Martínez J, Hernando Cubero J, Espinosa J, Martínez de Castro E, Ghanem I, Beato C, Blasco A, Garrido M, Bonilla Y, Mondéjar R, Arcusa Lanza MÁ, Aragón Manrique I, Manzano A, Sevillano E, Castañón E, Cardona M, Gallardo Martín E, Pérez Armillas Q, Sánchez Lasheras F, Ayala de la Peña F. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015 Feb;33(5):465–71. PMID: 25559804. DOI: 10.1200/JCO.2014.57.2347. IF2015: 20.982; D1. http://www.ncbi.nlm.nih.gov/pubmed/25559804 +Pubmed +DOI
• Goday A, Barneto I, García-Almeida JM, Blasco A, Lecube A, Grávalos C, Martínez de Icaya P, de las Peñas R, Monereo S, Vázquez L, Palacio JE, Pérez-Segura P. Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015 Oct;17(10):763–71. PMID: 26036853. DOI: 10.1007/s12094-015-1306-y. http://www.ncbi.nlm.nih.gov/pubmed/26036853 +Pubmed +DOI
• Iglesias Rey L, Fernández Pérez I, Barbagelata López C, Rivera Gallego A. [Venous thrombosis associated with central venous catheter use in patients with cancer]. Med Clin (Barc). 2015 Jan;144 Suppl(Suppl 1):41–3. PMID: 25771092. DOI: 10.1016/S0025-7753(15)30018-X. IF2015: 1.267; Q2. http://www.ncbi.nlm.nih.gov/pubmed/25771092 +Pubmed +DOI
• Maraver A, Fernandez-Marcos PJ, Cash TP, Mendez-Pertuz M, Dueñas M, Maietta P, Martinelli P, Muñoz-Martin M, Martínez-Fernández M, Cañamero M, Roncador G, Martinez-Torrecuadrada JL, Grivas D, de la Pompa JL, Valencia A, Paramio JM, Real FX, Serrano M. NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest. 2015 Feb;125(2):824–30. PMID: 25574842. DOI: 10.1172/JCI78185. http://www.ncbi.nlm.nih.gov/pubmed/25574842 +Pubmed +DOI
• Martínez-Fernández M, Dueñas M, Feber A, Segovia C, García-Escudero R, Rubio C, López-Calderón FF, Díaz-García C, Villacampa F, Duarte J, Gómez-Rodriguez MJ, Castellano D, Rodriguez-Peralto JL, de la Rosa F, Beck S, Paramio JM. A Polycomb-mir200 loop regulates clinical outcome in bladder cancer. Oncotarget. 2015 Dec;6(39):42258–75. PMID: 26517683. DOI: 10.18632/oncotarget.5546. http://www.ncbi.nlm.nih.gov/pubmed/26517683 +Pubmed +DOI
• Martínez-Fernández M, Feber A, Dueñas M, Segovia C, Rubio C, Fernandez M, Villacampa F, Duarte J, López-Calderón FF, Gómez-Rodriguez MJ, Castellano D, Rodriguez-Peralto JL, de la Rosa F, Beck S, Paramio JM. Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer. Clin Epigenetics. 2015;7:109. PMID: 26457124. DOI: 10.1186/s13148-015-0141-x. http://www.ncbi.nlm.nih.gov/pubmed/26457124 +Pubmed +DOI
• Martínez-Fernández M, Rubio C, Segovia C, López-Calderón FF, Dueñas M, Paramio JM. EZH2 in Bladder Cancer, a Promising Therapeutic Target. Int J Mol Sci. 2015 Nov;16(11):27107–32. PMID: 26580594. DOI: 10.3390/ijms161126000. http://www.ncbi.nlm.nih.gov/pubmed/26580594 +Pubmed +DOI
• Quintela ML, Mateos LL, Estévez SV, Calvo OF, Herranz UA, Afonso FJA, Santomé L, Aparicio LA. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor. Cancer Treat Rev. 2015 Mar;41(3):247–53. PMID: 25638257. DOI: 10.1016/j.ctrv.2014.12.006. IF2015: 7.983; D1. http://www.ncbi.nlm.nih.gov/pubmed/25638257 +Pubmed +DOI
• Quintero-Aldana G, Jorge M, Grande C, Salgado-Fernández M, Gallardo E, Varela S, López C, Villanueva MJ, Fernández A, Alvarez E, González P, Castellanos J, Casal J, López R, Campos Balea B. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer. Cancer Chemother Pharmacol. 2015 Oct;76(4):731–7. PMID: 26242221. DOI: 10.1007/s00280-015-2839-z. IF2015: 2.824; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26242221 +Pubmed +DOI
• Salvador J, Manso L, de la Haba J, Jaen A, Ciruelos E, de Villena MC, Gil M, Murias A, Galan A, Jara C, Bayo J, Baena JM, Casal J, Mel JR, Blancas I, Sanchez Rvira P. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clin Transl Oncol. 2015 Feb;17(2):160–6. PMID: 25119930. DOI: 10.1007/s12094-014-1210-x. IF2015: 2.075; Q3. http://www.ncbi.nlm.nih.gov/pubmed/25119930 +Pubmed +DOI
• Vázquez S, Villanueva M, Fírvida J, Campos B, Lázaro M, Huidobro G, Areses M del, Fernández N, Covela M, Casal J. Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. J Anal Oncol. 2015 Sep;4(3):94–101. DOI: 10.6000/1927-7229.2015.04.03.1. IF2015: N/A. http://www.lifescienceglobal.com/journals/journal-of-analytical-oncology/volume-4-number-3/89-abstract/jao/1769-abstract-erlotinib-as-second-line-therapy-for-patients-with-advanced-non-small-cell-lung-cancer-and-wild-type-egfr-tumors +DOI

Capítulos de libro

• Areizaga LM, Carrasco JA, de las Peñas R, Sala MÁ. Tumores mesenquimales de comportamiento localmente agresivo. In: Martín Brogo J, Valverde C, Cubedo R, Cruz J (eds.). Tratado de sarcomas de partes blandas. Madrid: NPG editorial; 2015. ISBN: 978-84-940238-4-2. http://www.mcu.es/webISBN/tituloDetalle.do?sidTitul=2189870&action=busquedaInicial&noValidating=true&POS=0&MAX=50&TOTAL=0&prev_layout=busquedaisbn&layout=busquedaisbn&language=es Enlace
• León L, Antón-Aparicio LM, Esteban-González E, Lázaro-Quintela M, Vázquez-Estévez S. Side Effects of Targeted Therapy. In: Bukowski RM, Figlin RA (eds.). Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Springer New York; 2015. p. 377–416. ISBN: 9781493916221; 9781493916214. https://www.scopus.com/inward/record.uri?eid=2-s2.0-84944617211&doi=10.1007%2F978-1-4939-1622-1&partnerID=40&md5=bf8e2dbe634de533fe761b000ee5ba2d +DOI
• Vázquez ML, Gallardo Martín E, Pena C, Lorenzo I, Constenla M. Capítulo 38. Cáncer Colorrectal no Polipósico. In: Pazos A, Ulla J (eds.). Abordaje multidisciplinar de cáncer colorrectal. 1st ed. Santiago de Compostela: Andavira Editora S.L.; 2015. p. 611–32. ISBN: 978-84-8408-795-3. http://www.andavira.com/ebooks/cancer_colorrectal/files/assets/basic-html/page-16.html# Enlace

Artículos Científicos

• Casal Rubio J, Fírvida-Pérez JL, Lázaro-Quintela M, Barón-Duarte FJ, Alonso-Jáudenes G, Santomé L, Afonso-Afonso FJ, Amenedo M, Huidobro G, Campos-Balea B, López-Vázquez MD, Vázquez S. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. Cancer Chemother Pharmacol. 2014 Mar;73(3):451–7. PMID: 24352251. DOI: 10.1007/s00280-013-2370-z. IF2014: 2.769; Q3. http://www.ncbi.nlm.nih.gov/pubmed/24352251 +Pubmed +DOI
• Fernández O, Afonso J, Vázquez S, Campos B, Lázaro M, León L, Antón Aparicio LM. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel. Anticancer Drugs. 2014 Mar;25(3):237–43. PMID: 24217332. DOI: 10.1097/CAD.0000000000000045. IF: 1.784; Q4. http://www.ncbi.nlm.nih.gov/pubmed/24217332 +Pubmed +DOI
• Juan O, Sánchez-Hernández A, Vázquez S, Casal J, Firvida JL, Aparisi F, Muñoz J, García-Sánchez J, Gironés R, Lázaro M, Giner V. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study. Anticancer Res. 2014 Apr;34(4):1959–66. PMID: 24692732. IF: 1.826; Q4. http://www.ncbi.nlm.nih.gov/pubmed/24692732 +Pubmed
• Santos M, Martínez-Fernández M, Dueñas M, García-Escudero R, Alfaya B, Villacampa F, Saiz-Ladera C, Costa C, Oteo M, Duarte J, Martínez V, Gómez-Rodriguez MJ, Martín ML, Fernández M, Viatour P, Morcillo MA, Sage J, Castellano D, Rodriguez-Peralto JL, de la Rosa F, Paramio JM. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res. 2014 Nov;74(22):6565–77. PMID: 25252918. DOI: 10.1158/0008-5472.CAN-14-1218. http://www.ncbi.nlm.nih.gov/pubmed/25252918 +Pubmed +DOI
• Vazquez S, Lazaro M, Luis Firvida J. Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile. Anticancer Drugs. 2014 Apr;25(4):368–74. PMID: 24384805. DOI: 10.1097/CAD.0000000000000066. IF: 1.784; Q4. http://apps.isiknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=4&SID=S2uGjT3vB4ldo5YTNQB&page=1&doc=7 +Pubmed +DOI